

Pharmacy Announcement

Effective Date for Preferred Drug List (PDL) Changes is Nov. 15, 2007

The effective date for changes to the Preferred Drug List (PDL) made by the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy is Nov. 15, 2007.

The following changes were made by the P&T Committee during its annual review of the PDL on June 21, 2007. The complete PDL is posted on the ["Preferred Drug List"](#) webpage.

Drug Class	Drugs Added	Drugs Removed	Drugs Reviewed But Not Added
Anti-Migraine Agents: Triptans	Relpax®	None	
Cardiovascular: Antihyperlipidemics: Statins and Statin Combinations	Pravastatin	Altoprev®	
Cardiovascular: Beta Blockers	Coreg CR®*	None	
Central Nervous System: ADHD/Stimulants	Concerta®	Methamphetamine (generic Desoxyn®)	
Ophthalmic Antihistamines	Alaway® Pataday® Zaditor OTC®	Zaditor®	
Respiratory: Inhaled Corticosteroids/Nebs	Advair HFA® Flovent HFA®	Flovent®**	Symbicort®
Cardiovascular: Antihyperlipidemics: Niacin Agents	Niaspan®***	None	

* For both Coreg® and Coreg CR®, prior authorization is not required if prescriber indicates an ICD-9CM diagnosis code of 428 (heart failure) on the prescription **OR** if the recipient is concurrently receiving a diuretic with either an Angiotensin II Receptor Blocker (ARB) agent **or** an Angiotensin-Converting Enzyme (ACE) inhibitor.

** Discontinued drug.

*** This action taken by the P&T Committee meeting held March 22, 2007.